Tafamidis
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Tafamidis
Tafamidis: Known uses and market status in India
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Tafamidis, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 4 |
| Evidence level | Not applicable |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| amyloidosis | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| ah amyloidosis |
| al amyloidosis |
| attrv122i amyloidosis |
India Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 238285 | VyndaMx 61mg Soft Gelatin Capsule | box of 30 soft gelatin capsules | Valid |
Safety Considerations
Drug Interactions: 12 interactions were recorded in the DDInter database; the pharmacology record also lists transthyretin as the drug’s target.
- Major: Ozanimod
- Moderate: Rosuvastatin, Deferasirox, Eltrombopag, Lusutrombopag, Artesunate, Axitinib, Methotrexate, Irinotecan, Irinotecan (liposomal), Belinostat, Imatinib
Please refer to the package insert for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.